These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 30921495)

  • 1. The role of mass spectrometry and related techniques in the analysis of extractable and leachable chemicals.
    Sica VP; Krivos KL; Kiehl DE; Pulliam CJ; Henry ID; Baker TR
    Mass Spectrom Rev; 2020 Mar; 39(1-2):212-226. PubMed ID: 30921495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perspectives on the PQRI Extractables and Leachables "Safety Thresholds and Best Practices" Recommendations for Inhalation Drug Products.
    Norwood DL; Nagao LM; Stults CL
    PDA J Pharm Sci Technol; 2013; 67(5):413-29. PubMed ID: 24084658
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Creating a Holistic Extractables and Leachables (E&L) Program for Biotechnology Products.
    Li K; Rogers G; Nashed-Samuel Y; Lee H; Mire-Sluis A; Cherney B; Forster R; Yeh P; Markovic I
    PDA J Pharm Sci Technol; 2015; 69(5):590-619. PubMed ID: 26429108
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Product Quality Research Institute (PQRI) Leachables and Extractables Working Group Initiatives for Parenteral and Ophthalmic Drug Product (PODP).
    Paskiet D; Jenke D; Ball D; Houston C; Norwood DL; Markovic I
    PDA J Pharm Sci Technol; 2013; 67(5):430-47. PubMed ID: 24084659
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reducing relative response factor variation using a multidetector approach for extractables and leachables (E&L) analysis to mitigate the need for uncertainty factors.
    Jordi MA; Rowland K; Liu W; Cao X; Zong J; Ren Y; Liang Z; Zhou X; Louis M; Lerner K
    J Pharm Biomed Anal; 2020 Jul; 186():113334. PubMed ID: 32387747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of UV-absorbing extractables from rubber closures used in containers of injectable powder and safety assessment of leachables in the drug.
    Wei Y; Wu Y; Zhu T; Li Z; Zhang Y
    J Pharm Biomed Anal; 2017 May; 138():256-266. PubMed ID: 28231528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A compilation of safety impact information for extractables associated with materials used in pharmaceutical packaging, delivery, administration, and manufacturing systems.
    Jenke D; Carlson T
    PDA J Pharm Sci Technol; 2014; 68(5):407-55. PubMed ID: 25336416
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Automated Solid Phase Extraction (SPE) LC/NMR Applied to the Structural Analysis of Extractable Compounds from a Pharmaceutical Packaging Material of Construction.
    Norwood DL; Mullis JO; Davis M; Pennino S; Egert T; Gonnella NC
    PDA J Pharm Sci Technol; 2013; 67(3):267-87. PubMed ID: 23752753
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Best practices for extractables and leachables in orally inhaled and nasal drug products: an overview of the PQRI recommendations.
    Norwood DL; Paskiet D; Ruberto M; Feinberg T; Schroeder A; Poochikian G; Wang Q; Deng TJ; DeGrazio F; Munos MK; Nagao LM
    Pharm Res; 2008 Apr; 25(4):727-39. PubMed ID: 18183477
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A Holistic Approach of Extractables and Leachables Assessment of Rubber Stoppered Glass Vial Systems for Biotechnology Products.
    Qi L; Liu J; Ronk M; Gallegos A; Fujimori K; Luo Y; Li K; Lee H; Nashed-Samuel Y
    J Pharm Sci; 2021 Nov; 110(11):3580-3593. PubMed ID: 34324943
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Standardization of Chromatographic Screening Methods for Organic Extractables and Leachables by Managing Outcomes.
    Jenke D
    PDA J Pharm Sci Technol; 2023; 77(4):329-338. PubMed ID: 37001885
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of leachables observed in the size exclusion chromatograms of a low concentration product stored in prefilled syringes.
    Valente JJ; Peddicord MB; Rinaldi FA; Kelly KA; Bolgar MS
    J Pharm Biomed Anal; 2017 May; 139():133-142. PubMed ID: 28279928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification and quantification of extractables and leachables in laminated film and pouches for pharmaceutical packaging.
    Fu C; Zhang X; Lei S; Zou M; Wang L; Jiao J; Yang Q
    J Pharm Biomed Anal; 2022 Oct; 220():115015. PubMed ID: 36054946
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of safety and quality impact of extractable and leachable substances in therapeutic biologic protein products: a risk-based perspective.
    Markovic I
    Expert Opin Drug Saf; 2007 Sep; 6(5):487-91. PubMed ID: 17877437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Principles for Management of Extractables and Leachables in Ophthalmic Drug Products.
    Houston CT; Rodrigues AD; Smith BB; Wang T; Richardson M
    PDA J Pharm Sci Technol; 2022; 76(3):278-294. PubMed ID: 35169039
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendation of Single Time Point Leachables Testing for Lyophilized Biotechnology Products Stored in Rubber Stoppered Glass Vial Systems.
    Gallegos A; Liu J; Ronk M; Qi L; Li K; Semin D; Nashed-Samuel Y
    J Pharm Sci; 2022 Jun; 111(6):1599-1604. PubMed ID: 35257694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Framework for sensitization assessment of extractables and leachables in pharmaceuticals.
    Parris P; Whelan G; Burild A; Whritenour J; Bruen U; Bercu J; Callis C; Graham J; Johann E; Griffin T; Kohan M; Martin EA; Masuda-Herrera M; Stanard B; Tien E; Cruz M; Nagao L
    Crit Rev Toxicol; 2022 Feb; 52(2):125-138. PubMed ID: 35703156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of an Adduct Impurity of an Active Pharmaceutical Ingredient and a Leachable in an Ophthalmic Drug Product Using LC-QTOF.
    Gollapalli R; Singh G; Blinder A; Brittin J; Sengupta A; Mondal B; Patel M; Pati B; Lee J; Ghode A; Kote M
    J Pharm Sci; 2019 Oct; 108(10):3187-3193. PubMed ID: 31226425
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Considerations when deriving compound-specific limits for extractables and leachables from pharmaceutical products: Four case studies.
    Parris P; Martin EA; Stanard B; Glowienke S; Dolan DG; Li K; Binazon O; Giddings A; Whelan G; Masuda-Herrera M; Bercu J; Broschard T; Bruen U; Callis CM; Stults CLM; Erexson GL; Cruz MT; Nagao LM
    Regul Toxicol Pharmacol; 2020 Dec; 118():104802. PubMed ID: 33038429
    [TBL] [Abstract][Full Text] [Related]  

  • 20. On developing a process for conducting extractable-leachable assessment of components used for storage of biopharmaceuticals.
    Wakankar AA; Wang YJ; Canova-Davis E; Ma S; Schmalzing D; Grieco J; Milby T; Reynolds T; Mazzarella K; Hoff E; Gomez S; Martin-Moe S
    J Pharm Sci; 2010 May; 99(5):2209-18. PubMed ID: 20039383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.